Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All drugs

Regorafenib (off Label)

Stivarga

Stage Phase 2

Sponsor Memorial Sloan Kettering (investigator)

Route oral

Modality small molecule

Class multi-kinase TKI

Mechanism VEGFR, KIT, RET and others (label class)

Target VEGFR1 to 3 (KDR, FLT1, FLT4) (TEC-0075)

Sources

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT02098538

Regorafenib in progressive R/M ACC, registry NCT02098538, results posted 09.10.2025 (registry; opened 2026-10-27): n 38; CR plus PR in 1 participant; serious AEs 14 of 38; best response and survival counts as posted.

Brief source A29

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT02098538

A Phase II Study of Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

Regorafenib in ACC

Registry NCT02098538

Phase Phase 2

Status Completed

Enrollment 38

Start 2014-03

Primary completion 2024-11-07

Study completion 2024-11-07

Regorafenib

Dose not stated in source

Population progressive R/M ACC (n = 38)

Estimand Single arm

responders (CR or PR): 1 patients (of 38), results posted 09.10.2025

patients with serious adverse events: 14 patients (of 38), results posted